Cardinal Health's 2026 Report Highlights Biosimilars' Impact on Oncology and Patient Care

Biosimilars Set to Transform Oncology and Patient Care, Says Cardinal Health's 2026 Report

Cardinal Health has released its 2026 Biosimilars Report, which underscores the transformative potential of biosimilars in the healthcare landscape, particularly within oncology. Since their introduction in 2015, biosimilars have generated over $56 billion in cost savings, significantly enhancing patient access to effective treatments. This report, informed by insights from 101 physician practices, reveals a remarkable statistic: nearly 99% of healthcare providers feel comfortable discussing biosimilars with their patients. This strong clinical confidence underscores a growing acceptance of these alternatives to traditional biologics, which is crucial in the ongoing effort to improve health outcomes and reduce costs.

The report highlights several key factors that will influence the future of biosimilar adoption. Notably, reimbursement stability emerges as a critical concern among providers, with 68% citing it as "very important" for continued investment in biosimilars. Furthermore, 59% prefer stable discount models over fluctuating reimbursement environments. This emphasis on consistency is essential to prevent a potential “biosimilar void,” which could hinder patient access to these vital therapies. In oncology, biosimilars have already achieved an impressive average market share of 81% within five years of their launch, suggesting a strong trend that Cardinal Health anticipates will persist as new products enter the market.

Looking forward, the report projects that approximately 25 new biosimilars will gain FDA approval across various therapeutic fields, including immunology and retina, within the next two years. With favorable market and policy conditions, there is the potential to generate up to $181 billion in healthcare savings. Cardinal Health remains committed to guiding providers through the complexities of reimbursement to ensure that patients have access to innovative and effective biosimilar treatments. As the company continues its advocacy for biosimilars, it plans to leverage the insights from this report to shape strategies that enhance patient care and support healthcare professionals in adopting these crucial therapies.

In addition to the robust clinical findings, Cardinal Health emphasizes the importance of ongoing education and resources for providers on the benefits of biosimilars. By facilitating discussions and providing tools for effective integration, the company seeks to build provider confidence further and maximize patient access to these life-saving medications. For those interested in a deeper dive into the findings of the report, the full document is available on Cardinal Health's website, showcasing their commitment to transparency and thought leadership in the healthcare arena.